Candid Therapeutics completed the acquisition of Vignette Bio and TRC 2004 for $370m.

Candid Therapeutics, a biotechnology company, completed the acquisition of Vignette Bio, which focuses on leveraging data science and scientific rigor to accelerate the development of innovative products and therapies, and TRC 2004, a biotechnology company, for $370m. “TCE antibodies have the most promise as scalable and patient friendly drugs to deplete B cells for treatment of a myriad of autoimmune conditions and represents a once in a generation development opportunity. The drugs we are developing at Candid have the potential to go above and beyond the clinical and commercial success of Humira and Rituxan and I am thrilled to be leading the Candid team knowing we can possibly make history by changing the paradigm in how autoimmune diseases are treated,” Dr. Ken Song, Candid Therapeutics Chairman, President, and CEO.